Wellvone, Suspension

7680535630151 CH-53563 suspension
Wellvone, Suspension
Wellvone, Suspension
Wellvone, Suspension
1 / 3
google

Article details

Package size
210
Selling units
210
Measure
ml
Galenic form
suspension
Galenic group
unbekannt

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
30/07/2025
Patient information leaflet
Français
30/07/2025
Patient information leaflet
Italien
30/07/2025
Summary of Product Characteristics
Allemand
30/07/2025
Summary of Product Characteristics
Français
30/07/2025
Summary of Product Characteristics
Italien
30/07/2025

Detailed composition

Substance Quantity Type Category
(N/A)
750.0 MG Substance Wirkstoff (Principe actif)
(N/A)
50.0 MG Substance HBESI
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance AIMDK
(N/A)
0.95 MG Substance HBESI
(N/A)
- Substance AROMA
(N/A)
- Substance AROMA
(N/A)
- Substance AROMA
(N/A)
- Substance Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration)
(N/A)
0.66 MG Substance HBESI
(N/A)
- Substance AIMDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK

Reimbursement information

Public price
CHF 486.40
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 15/03/1997

Authorization holder

GlaxoSmithKline AG

6340 Baar

Authorization information

Swissmedic authorization number
53563
Drug name
Wellvone, Suspension
Galenic form
SUOR
ATC Code
P01AX06
Authorization status
Z
Dispensing category
A
First authorization
29/05/1996
Authorization expiration date
31/12/9999
IT Number
08.04.3.
Domain
Human medicine
Field of application
Pneumocystis carinii Pneumonie

Package details

Description (FR)
WELLVONE susp 750 mg/5ml 210 ml
Description (DE)
WELLVONE Susp 750 mg/5ml 210 ml
Market launch
29/05/1996
Narcotic (BTM)
No